Trial · NCT07901101
Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator
NCT07901101, Phase 4, Not yet recruiting, University of South Florida
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator. Trials, record NCT07901101. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901101
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator
- NCT number
- NCT07901101
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 50 participants, estimated
- Lead sponsor
- University of South Florida
- Conditions
- HIV Prevention, Pre-Exposure Prophylaxis (PrEP)
- Interventions
- RAPID Response peer navigation, Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Acceptability Score on the RAPID Response Acceptability Questionnaire | Day 0 (before emergency department discharge) | Mean of 14 items based on the Theoretical Framework of Acceptability (TFA), each rated 1 (strongly disagree) to 5 (strongly agree). Possible range 1-5; higher scores mean greater acceptability of starting PrEP in the emergency department. |
| Secondary | Mean Acceptability Score at Follow-up | 48-72 hours, 30 days, 60 days, 90 days and 365 days after discharge | Same 14-item TFA-based score (range 1-5; higher = greater acceptability), reported separately at each timepoint. |
| Secondary | Percentage of Approached Patients Who Enroll | Throughout enrollment, up to 6 months | Number of patients who consent divided by the number of patients aged 18 or older approached by the peer navigator, as a percentage. |
| Secondary | Number of Participants Who Take the First PrEP Dose | Up to 72 hours after discharge | Count of enrolled participants whose first dose is observed in the emergency department or, by exception, by video or in person within 72 hours |
| Secondary | Percentage of Participants Linked to PrEP Care at 30 Days | 30 days after discharge | Percentage of participants who attend a visit with a community PrEP provider within 30 days of discharge, confirmed by the navigator. |
| Secondary | Percentage of Participants Linked to PrEP Care at 90 Days | 90 days after discharge | Percentage of participants with a confirmed visit with an ongoing PrEP provider by 90 days. |
| Secondary | Percentage of Participants Still Taking PrEP | 90 days and 365 days after discharge | Percentage of participants who report taking PrEP at the time of contact. |
| Secondary | Percentage of Participants With Follow-up PrEP Laboratory Testing | 120 days after discharge | Percentage of participants whose outside PrEP provider confirms follow-up PrEP labs and a PrEP prescription. |
| Secondary | Change in PrEP Knowledge Score | Day 0, before and after education | Number correct on a 9-item true/false PrEP knowledge check (range 0-9; higher = more knowledge), after education minus before education. |
| Secondary | Number of Participants With a New HIV Diagnosis After Starting PrEP | Up to 365 days after discharge | Count of participants with a positive HIV result after the first dose, including a positive confirmatory HIV-1 RNA test after discharge. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07901101
GET https://conductscience.org/api/trials/v1/NCT07901101/registered